ArticleTranslational gastroenterology and hepatology2026
CT-defined sarcopenia as a predictive factor in patients undergoing portal vein embolization: a systematic review and meta-analysis.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia can be assessed by cross-sectional imaging and is a prognostic imaging marker in several diseases and tumor entities. First reports demonstrated a significant impact of the presence of sarcopenia on the outcome of portal vein embolization (PVE). The present analysis sought to investigate the effect of computed tomography (CT)-defined sarcopenia in patients undergoing PVE based on a meta-analysis. Methods: MEDLINE library was screened for papers analyzing the association between CT-defined sarcopenia/low skeletal muscle mass and the treatment outcome of PVE up to February 2026. The primary endpoints of the systematic review were the increase or the volume or the growth rate per week of mean future liver remnant (FLR) in % between the groups stratified by sarcopenia. The random-effect model was used for the statistical analysis. Results: The meta-analysis comprised a total of seven studies with 599 patients with different malignant tumors undergoing PVE. For the effect of the future liver remnant volume (FLRV), the pooled mean difference (MD) between the sarcopenic and non-sarcopenic group was 2.70% [95% confidence interval (CI): 0.31-5.09], P=0.03, favoring non-sarcopenia. For the effect of the FLRV increase in %, the pooled MD between the sarcopenic and non-sarcopenic group was 10.87% (95% CI: 3.45-18.30), P=0.004. The pooled correlation coefficient between the skeletal muscle index (SMI) and the liver growth rate after PVE was 0.40 (95% CI: 0.17-0.63), P<0.001. Conclusions: No statistically effects were identified for the impact on resection rate, 90-day mortality and postoperative liver failure. CT-defined sarcopenia has a statistically but not clinically impact on the FLR in patients undergoing PVE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.